Clinical trial
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
NCT00182052 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00182052 |
|---|---|
| Title | Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer |
| Official title | Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer: A Randomized Double-Blind, Placebo Controlled Phase III Study |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | Rosiglitazone, Placebo |
| Enrollment | 100 |
| Start date | Sep 1, 2000 |
| Primary completion | Aug 1, 2003 |
| Completion | Aug 1, 2003 |
| First posted | Sep 16, 2005 |
| Last update posted | May 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: